Presenting at CannMed 24 was a tremendous experience. This is a must-attend conference for those new to the field and for those looking to advance cannabis research and science! - Mitchell L. Doucette, PhD, MS CannMed 24 is a conference focusing on cannabis science, innovation, and collaboration with the aim of advancing the industry and improving patient care. Thank you to the CannMed Events organizers for your commitment to fostering collaboration and driving meaningful discourse. Until next time! #CannabisConferences #CannabisResearch
Leafwell’s Post
More Relevant Posts
-
A machine-readable, digital protocol and enterprise MDR are core to digitalizing dataflow and automating processes and documentation generation. If you are attending #dpharm2023, be sure to catch Nurocor, Inc’s presentation
Addressing the Innovation Gap: How Nurocor Drives Innovation in Clinical Trials Are you going to DPharma 2023 in Boston? Please attend the distinguished DPharm Idol Disrupt session Thursday (September 21) at 4:30PM. Maria Perkinson (Nurocor SVP, Process and Technology Optimization) will present on How Nurocor Drives Innovation in Clinical Trials to help patients through a scalable and sustainable future for clinical development. #DPHARM2023 #DigitalInnovation #DigitalProtocol #Nurocor
To view or add a comment, sign in
-
The Pharma R&D Annual Review 2024 is out now! For over 30 years, Citeline has tracked how the climate is shifting, revealing the currents and tides that shape the drug development landscape. Download the full report today. https://ow.ly/fp9650R8P6r
Citeline Clinical on LinkedIn: #pharmarnd #annualreview #pharmatrends
linkedin.com
To view or add a comment, sign in
-
👏🏽 Amazing panel featuring Marcy Kravet of Inato, Jamila Watkins, MBA of Chinook Therapeutics, a Novartis Company, Patricia Cornet, MA and Melissa Cabral of Bristol Myers Squibb to educate us on including and applying insights from the patient voice in drug development before, during and after research. Here are some key takeaways from our dialogue at the #oectkpm summit: 🔍 For small biotechs, while resources are slim, coordinating a multifaceted approach can be easier 🌏 Diversity encompasses a spectrum far broader than race and ethnicity (yes, we still have to remind everyone!) 📚 Health literacy isn't merely about readability; it's about ensuring information is comprehensible and actionable for all 🏡 We must extend our considerations beyond clinical settings and factor in home life dynamics and their loved ones (pets included!) 💡 And let's not forget the treasure trove of patient insights waiting to be tapped into at research sites — truly invaluable for driving impactful outcomes #PatientVoice #DrugDevelopment #HealthcareInnovation #ClinicalResearch #ClinicalOperations #OECT
To view or add a comment, sign in
-
Developing a new drug takes long-term commitment but the reward can be life-changing. Watch this video as Race Oncology CEO speaks with HotCopper to break down the drug development process and biotech companies' appeal to the investors. #oncologydrugs #biotech #investment
We were lucky to have been invited to participate in a HotCopper webinar last week which delved into the topic of “Demystifying clinical trials and approval processes for ASX-listed companies”. Race Oncology CEO Dr Daniel Tillett joined Hot Copper's Sonia Madigan to discuss Race's journey through the drug development process with our drug #bisantrene and why #biotech investments can pay dividends for patient investors. Watch the interview here: https://lnkd.in/g93jQK3f #BiotechInvestment #CancerTreatment #cardioprotection
Race CEO Daniel Tillett Joins Hot Copper webinar to discuss bringing medical developments to market
https://www.youtube.com/
To view or add a comment, sign in
-
Learn to Love again! 👩❤️👩 Thank you very much William Hirst for this article. I have worked for more than 10 years for the healthcare industry and always wondered why people were hating pharma so much ? This is probably the industry that has saved the most number of lives. It is said that one out of two child beeing born nowadays will live more than 100 years old. This is definetly due to #medical #innovation as a whole. This is also very true that the #patient must be at the center of all things but they have never been considered by the pharmaceutical industry. They cure disease, they do not treat patient, which is the paradigm that needs to change. Of course this is easy to understand as pharma companies are BtoPtoPtoP companies, especially in Europe. Business to Payers to Practionners to Patients. Patient is at the far end of their value chain. You always ear in pharma : "We cannot talk to patient". It is such a burden for them to close the gap between business and patient. All other indsutries are allowed to talk to their customers. To improve Pharma / Patient relationship we should definetly start by openning the conversations and work together on the common goal that both are sharing : "Living better lives" ! I am sure that there will be some fascinating conversations at PhArmageddon Europe with the shaking ideas Paul Simms https://lnkd.in/e7jjXDRX
To view or add a comment, sign in
-
Insightful panel on #biotech commercialisation here at Day 2 of LSX - partnering for Life Science eXecutives , with experienced biotech keaders including Francis Pang. key takeways: 🧭 build a joined-up value strategy considering not just HTA/payer perspectives but HCPs, patients, regulators and policy-makers ⏰ start value & access thinking early, before pivotal trial design, not leaving it till peri-launch 👩🔬 plan ev gen for reimbursement as well as regulatory approval, even if you expect a partner to ultimately commercialise 💸 manage spend as a clinical-stage biotech by leveraging external market access expertise and thought partners #MarketAccess #Value #Commercial #Medical
To view or add a comment, sign in
-
Clinical Trials Assistant 🔬| Passionate About Advancing Healthcare & Bridging Science & Patient Care🌱🩹| Fueled by the vital backbone of eTMF filing and administration in revolutionizing clinical research 🚀
💚 Why I LOVE Being Part of AK Clinical Research 💚 Strong team? Check ✅ Solid partners? Double-check. ✅✅ Together, we’re like the Avengers of clinical trials, but instead of fighting bad guys, we're battling health challenges. Since we began in 2019, we have embarked on 25 clinical trials, each one pushing us to new heights. Talk about a hive of activity! 🐝- - - - 🌱 🖐 Need a helping hand? 🖐 🔗 Join our journey! Follow AK Clinical Research here on LinkedIn to get updates and insights into the work we do and the difference we make. Still curious about our superpowers? Check out our website to learn more! https://lnkd.in/ddFFQ3EU #ProudTeamMember #ClinicalTrials #HealthcareInnovation #Teamwork #CRO #Biotech #ResearchExcellence
Proud Milestone Alert! 🚀 Since our establishment in 2019, our team at AK Clinical Research has been dedicated to advancing healthcare through clinical trials. 🌍 We've contributed to 25 Clinical trials encompassing observational studies, diagnostic investigations, and pivotal drug and device trials across diverse therapeutic areas. Each trial has been a step forward in improving patient care and treatment options. These accomplishments have enabled us to develop a robust and integrated network of partners. This network supports our full-service delivery model, ensuring the efficient conduct and successful completion of clinical trials. 👏 A huge thank you to our dedicated team and partners for their unwavering commitment to innovation and excellence in healthcare research. Let's continue driving progress and making a difference together! #ClinicalTrials #HealthcareInnovation #ResearchExcellence #Teamwork #CRO #Biotech
To view or add a comment, sign in
-
Speaker/Panelist Acquisition for BioPharma Nexus Conference (22nd- 23rd Oct 2024), New Jersey, USA | (14th-15th Nov, 2024), London, UK
Happy New Year 2024 from the entire BioPharma Nexus Conference community! May this year be a beacon of innovation, collaboration, and unparalleled success. Here's to achieving new heights together. Wishing you joy, prosperity, and a year filled with exciting possibilities. Happy New Year! #biopharma #nexus #conference #clinicaltrials #medical #patientrecruitment #clinicaldatamanagement #clinicaldevelopment #clinicaloperations #medicalaffairs #patientadvocacy
To view or add a comment, sign in
-
The ball has dropped on the healthcare and life sciences industry’s unique New Year tradition, the J.P. Morgan Healthcare Conference, so all eyes turn to 2024. To help define a path forward, Morgan Lewis FDA and healthcare partners Jacqueline Berman, Rebecca Dandeker, Maarika Kimbrell, and Kathleen Sanzo have assembled an in-depth report on drug and biologic developments at the FDA. From clinical trial developments and manufacturing to advertising and compliance, the report can provide companies with useful information on any stage of product development and marketing. Read the full report and find our selection of notable takeaways below. #mllifesci #wearemorganlewis
Pharma’s Almanac: Forecast at the Turn of the Year
morganlewis.com
To view or add a comment, sign in
-
“The biopharma industry depends on volunteers to participate in clinical trials that are not designed to help them. It is how we advance science and get new treatments to the world. Yet our industry is not doing enough to reduce the burden on volunteers in clinical trials.” It’s going to take commitment from the entire industry to create a more accessible environment for clinical trial participants. Adaptive Research supports every action we can take to democratize clinical trial access. Check out this In Vivo article for seven ideas: https://lnkd.in/gszi5ixr #clinicaltrials #clinicalresearch #patientrecruitment #clinicaltrialdiversity
To view or add a comment, sign in
2,479 followers